1215766-76-9

1215766-76-9 structure

Name: NBI 27914 hydrochloride
Chemical Name: 5-Chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine hydrochloride (1:1)
CAS Number: 1215766-76-9
Molecular Formula: C₁₈H₂₁Cl₅N₄
Molecular Weight: 470.651
Catalog: Signaling Pathways GPCR/G Protein CRFR
Create Date: 2021-01-07 02:35:59
Modify Date: 2025-08-27 13:50:02
NBI-27914 (hydrochloride) is a selective Corticotropin-Releasing Factor 1 (CRF1) receptor antagonist with a Ki value of 1.7 nM[1][3][4].

Name	5-Chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine hydrochloride (1:1)
Synonyms	4,6-Pyrimidinediamine, 5-chloro-N4-(cyclopropylmethyl)-2-methyl-N4-propyl-N6-(2,4,6-trichlorophenyl)-, hydrochloride (1:1) 5-Chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine hydrochloride (1:1) MFCD05662281 5-Chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)pyrimidine-4,6-diamine hydrochloride (1:1)

Description	NBI-27914 (hydrochloride) is a selective Corticotropin-Releasing Factor 1 (CRF1) receptor antagonist with a Ki value of 1.7 nM[1][3][4].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> CRFR Research Areas >> Neurological Disease
Target	Ki: 1.7 nM (CRF1 receptor)[4]
In Vivo	NBI 27914 (3~30 mg/kg; i.p.) hydrochloride attenuates the referred abdominal pain at the highest dose tested, it is efficacious both 4 and 24 h post-indomethacin dosing[1]. NBI 27914 (1~10 mg/kg; i.p.) hydrochloride dose dependently attenuates Freund's Complete Adjuvant-induced mechanical hyperalgesia. NBI 27914 (10 mg/kg) hydrochloride reverses the thermal hyperalgesia. NBI 27914 hydrochloride attenuates spinal nerve ligation-induced mechanical hyperalgesia and tactile allodynia with minimal effective doses equal to 5 and 10 mg/kg, respectively[1]. The higher doses of NBI 27914 hydrochloride blocks the behavioral seizures and prevents epileptic discharges in concurrent electroencephalograms recorded from the amygdala[2]. Animal Model: Male CD-1 mice (20~25 g)[1] Dosage: 3~30 mg/kg Administration: I.p. Result: Attenuated the referred abdominal pain at the highest dose tested, it was efficacious both 4 and 24 h post-indomethacin dosing.
References	[1]. Peng YL, et al. Central Neuropeptide S inhibits food intake in mice through activation of Neuropeptide S receptor. Peptides. 2010;31(12):2259-2263. [2]. Hummel M, et al. Pain is a salient "stressor" that is mediated by corticotropin-releasing factor-1 receptors. Neuropharmacology. 2010;59(3):160-166. [3]. Baram TZ, et al. The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Res. 1997;770(1-2):89-95. [4]. Chen C, et al. Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J Med Chem.

Molecular Formula	C₁₈H₂₁Cl₅N₄
Molecular Weight	470.651
Exact Mass	468.020874

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1215766-76-9	184241-44-9
1782228-59-4	855527-92-3
93965-89-0	1048649-80-4
61535-49-7	36362-09-1
669073-77-2	160901-63-3
1803586-71-1	748158-65-8
76008-63-4	148014-39-5
444606-74-0	1083245-90-2
350597-51-2	940515-36-6
13176-67-5	167772-13-6